RP-HPLC Method Development and Validation for Simultaneous Quantitative Estimation of Montelukast Sodium and Desloratadine in Intranasal Drug Delivery
International Journal of Drug Delivery Technology · 25.04.2026 · 16 (19s)
DOI: 10.25258/ijddt.16.19s.78 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 25.04.2026. Verfasst von Mahesh Shankar Kadam und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Background
The concurrent administration of a leukotriene receptor antagonist (Montelukast Sodium) and a secondgeneration antihistamine (Desloratadine) via the intranasal route presents a synergistic therapeutic strategy for allergic rhinitis, bypassing hepatic first-pass metabolism and accelerating the onset of action.
Objective
The current study aimed to develop and comprehensively validate a rapid, specific, and robust reversephase high-performance liquid chromatography (RP-HPLC) method for the simultaneous quantitative estimation of both active pharmaceutical ingredients within a novel intranasal formulation.
Methods
Chromatographic separation was achieved under isocratic conditions utilizing a C18 analytical column (150 mm x 4.6 mm, 5 um). The optimized mobile phase consisted of a binary mixture of acetonitrile and phosphate buffer (pH 3.5) in a 50:50 (v/v) ratio, delivered at a constant flow rate of 1.0 mL per minute. The column effluent was monitored at an isosbestic wavelength of 230 nm using a PDA detector.
Results
The analytes demonstrated excellent baseline resolution, with Desloratadine and Montelukast Sodium eluting at retention times of approximately 3.4 minutes and 6.8 minutes, respectively. The method exhibited strict linearity over the concentration ranges of 5.0 to 37.5 ug per mL for Desloratadine and 10.0 to 75.0 ug per mL for Montelukast Sodium, with correlation coefficients R squared exceeding 0.999. Accuracy was confirmed with mean recovery rates between 99.36 percent and 100.90 percent. Both intra-day and inter-day precision demonstrated percent RSD less than 2.0 percent.
Conclusion
The developed analytical method is highly sensitive, accurate, and fully compliant with ICH Q2(R1) validation guidelines, making it highly applicable for routine quality control, stability monitoring, and batch release testing of complex intranasal drug delivery systems.
Zitieren
APA
Kadam, M. S., Patil, S. S., Sharma, K., Mittal, S., Sharma, S. K., Simran, S., Kharde, S. N., & M, P. (2026). RP-HPLC Method Development and Validation for Simultaneous Quantitative Estimation of Montelukast Sodium and Desloratadine in Intranasal Drug Delivery. International Journal of Drug Delivery Technology, 16(19s). https://doi.org/10.25258/ijddt.16.19s.78
Vancouver
Kadam MS, Patil SS, Sharma K, Mittal S, Sharma SK, Simran S, et al. RP-HPLC Method Development and Validation for Simultaneous Quantitative Estimation of Montelukast Sodium and Desloratadine in Intranasal Drug Delivery. International Journal of Drug Delivery Technology. 2026;16(19s). doi:10.25258/ijddt.16.19s.78
BibTeX
@article{Kadam2026,
author = {Kadam, Mahesh Shankar and Patil, Suyog Shridhar and Sharma, Kirti and Mittal, Stuti and Sharma, Sachin Kumar and Simran, Simran and Kharde, Sagar Nanasaheb and M, Parameshwari},
title = {RP-HPLC Method Development and Validation for Simultaneous Quantitative Estimation of Montelukast Sodium and Desloratadine in Intranasal Drug Delivery},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {19s},
doi = {10.25258/ijddt.16.19s.78}
}
EUVIMED